Elevated Mortality Risk from CRKp Associated with Comorbidities: Systematic Review and Meta-Analysis

• Main Authors: Lucas Candido Gonçalves Barbosa (Author), José Arthur Silva e Sousa (Author), Graziela Picciola Bordoni (Author), Gabriel de Oliveira Barbosa (Author), Lilian Carla Carneiro (Author)
• Format: Book
• Published: MDPI AG, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics11070874; 2079-6382
• Keywords: mortality; health public; <i>Klebsiella pneumoniae</i>; carbapenems; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 11, Iss 7, p 874 (2022)

Carbapenem-resistant <i>Klebsiella pneumoniae</i> has become a public health problem with therapeutic limitations and high mortality associated with comorbidities. Methods: This is a systematic review and meta-analysis with a search in PubMed, SciELO, and Lilacs. Ten articles were selected, considering cohort, case-control, and cross-sectional studies. Tests for proportions and relative risk of mortality were performed, considering a 5% threshold for significance. Statistical analyses were performe dusing Rstudio^® software, version 4.0.2 of Ross Ihaka and Robert Genleman in Auckland, New Zealand. Results: <i>Klebsiella pneumoniae</i>, associated with chronic kidney disease, was responsible for 26%/258 deaths, chronic lung disease 28%/169, diabetes 31%/185, liver disease 15%/262, and heart disease 51%/262 deaths. Carbapenem-resistant <i>Klebsiella pneumoniae</i> associated with chronic kidney disease was responsible for 49%/83 deaths, with diabetes 29%/73, and with liver disease 33%/73 deaths. The risk of death from carbapenem-resistant <i>Klebsiella pneumoniae</i> was twice as high as the number of deaths associated with carbapenem-sensitive <i>Klebsiella pneumoniae</i>, RR = 2.07 (<i>p</i> < 0.00001). Conclusions: The present study showed an increase in mortality from carbapenem-resistant <i>Klebsiella pneumoniae</i> when associated with comorbidities.